Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets

Executive Summary

Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.

You may also be interested in...



Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating

Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.

Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating

Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.

APA Update: New Antidepressants Elbow Into Crowded Market

Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel